To explain the discrepancy between mutation rates and spectra of normal vs. tumor samples from heterozygous carriers of POLD1 exonuclease pathogenic variants, we considered the possibility of somatic inactivation of the exonuclease function in the second copy of POLD1 in the ultra- or hyper-mutated tumors. This evidence concerns the gene POLD1 and neoplasm.